ST段抬高型心肌梗死患者药物洗脱支架植入后不久出现严重血小板减少症。
Severe thrombocytopenia soon after drug-eluting stent implantation in ST-elevation myocardial infarction.
作者信息
Łebek-Szatańska Agnieszka, Pośnik-Kisło Anna, Błaszak-Ciećwierska Wiesława, Dąbrowski Marek
机构信息
Cardiology Clinical, Physiotherapy Division, 2 Faculty of Medicine, Medical University of Warsaw, Bielański Hospital, Warsaw, Poland.
出版信息
Postepy Kardiol Interwencyjnej. 2015;11(4):354-6. doi: 10.5114/pwki.2015.55614. Epub 2015 Jan 12.
Abstract
Thrombocytopenia is among the most frequent haematological issues in patients hospitalised with myocardial infarction. We discuss the case of a 77-year-old male who was admitted to hospital on the 4(th) hour of ST-elevation myocardial infarction of the anterior wall. A percutaneous coronary intervention to critically stenoted initial segment of the anterior descending branch was performed. A few days later he started developing symptomatic thrombocytopenia. On the course of his long hospitalization we faced many important problems, concerning both diagnosis and treatment of these co-existing conditions.
摘要
血小板减少症是心肌梗死住院患者中最常见的血液学问题之一。我们讨论一例77岁男性患者，其在发生前壁ST段抬高型心肌梗死4小时后入院。对严重狭窄的前降支起始段进行了经皮冠状动脉介入治疗。几天后，他开始出现有症状的血小板减少症。在其漫长的住院过程中，我们面临了许多关于这些并存病症的诊断和治疗的重要问题。
相似文献
1
Severe thrombocytopenia soon after drug-eluting stent implantation in ST-elevation myocardial infarction.
Postepy Kardiol Interwencyjnej. 2015;11(4):354-6. doi: 10.5114/pwki.2015.55614. Epub 2015 Jan 12.
2
Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
Diab Vasc Dis Res. 2015 Sep;12(5):306-14. doi: 10.1177/1479164115592252. Epub 2015 Jul 6.
3
5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
JACC Cardiovasc Interv. 2011 Jan;4(1):24-9. doi: 10.1016/j.jcin.2010.11.003.
4
Late-acquired incomplete stent apposition after everolimus-eluting stent versus sirolimus-eluting stent implantation in patients with non-ST-segment elevation myocardial infarction and ST-segment elevation myocardial infarction.
EuroIntervention. 2016 Oct 10;12(8):e979-e986. doi: 10.4244/EIJY15M09_12.
5
Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).
JACC Cardiovasc Interv. 2014 Oct;7(10):1093-102. doi: 10.1016/j.jcin.2014.04.017. Epub 2014 Sep 17.
6
[Efficacy comparison of primary percutaneous coronary intervention by drug-coated balloon angioplasty or drug-eluting stenting in acute myocardial infarction patients with de novo coronary lesions].
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):600-607. doi: 10.3760/cma.j.cn112148-20200327-00254.
7
Percutaneous coronary intervention with stenting of left main coronary artery with drug-eluting stent in the setting of acute ST elevation myocardial infarction.
Int J Cardiol. 2008 May 23;126(2):224-8. doi: 10.1016/j.ijcard.2007.03.131. Epub 2007 May 10.
8
9
Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
JACC Cardiovasc Interv. 2014 Aug;7(8):849-56. doi: 10.1016/j.jcin.2014.02.016.
10
Mesh-covered embolic protection stent implantation in ST-segment-elevation myocardial infarction: final 1-year clinical and angiographic results from the MGUARD for acute ST elevation reperfusion trial.
Circ Cardiovasc Interv. 2015 Feb;8(2):e001484. doi: 10.1161/CIRCINTERVENTIONS.114.001484.
本文引用的文献
1
Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.
Ther Adv Hematol. 2012 Aug;3(4):237-51. doi: 10.1177/2040620712443537.
2
Pulmonary embolism caused by delayed heparin-induced thrombocytopenia in a patient who received prophylactic LMWH.
Am J Case Rep. 2012;13:118-21. doi: 10.12659/AJCR.883107. Epub 2012 Jun 20.
3
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24.
4
HITlights: a career perspective on heparin-induced thrombocytopenia.
Am J Hematol. 2012 May;87 Suppl 1:S92-9. doi: 10.1002/ajh.23127. Epub 2012 Feb 24.
5
Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.
Am Heart J. 2011 Feb;161(2):298-306.e1. doi: 10.1016/j.ahj.2010.10.035.
6
Possible case of levofloxacin-induced thrombocytopenia.
Am J Health Syst Pharm. 2011 Jan 1;68(1):43-6. doi: 10.2146/ajhp090564.
7
The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity.
Expert Rev Clin Immunol. 2007 Jul;3(4):623-35. doi: 10.1586/1744666X.3.4.623.
8
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.
9
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
Circulation. 2009 May 12;119(18):2454-62. doi: 10.1161/CIRCULATIONAHA.108.827162. Epub 2009 Apr 27.
10
Thrombocytopenic conditions-autoimmunity and hypercoagulability: commonalities and differences in ITP, TTP, HIT, and APS.
Am J Hematol. 2005 Nov;80(3):232-42. doi: 10.1002/ajh.20408.
Zotero 插件